BD (Becton, Dickinson and Company), a prominent entity in the global medical technology sector, recently announced a significant leadership change. Executive Vice President and Chief Financial Officer Chris DelOrefice will leave the company on December 5, 2025, to explore new professional ventures. In the interim, Vitor Roque, the Senior Vice President of Finance, will assume the CFO role during this transition.
Strategic CFO Transition at BD
Chris DelOrefice has been a vital member of BD’s Executive Leadership Team for four years. Under his guidance, the company successfully executed its BD 2025 strategy, enhancing its product portfolio to meet the evolving demands of the healthcare landscape. Tom Polen, chairman and CEO of BD, praised DelOrefice’s contributions and expressed confidence in Roque’s capabilities.
Roque’s experience spans over two decades within BD, involving critical finance leadership roles across various regions and business units. His deep understanding of the company and its operations positions him well for the interim CFO role.
Preliminary Revenue Results
Alongside the leadership announcement, BD released its preliminary revenue results for the fourth quarter and fiscal year 2025, which ended on September 30, 2025. The key results are as follows:
- Fourth Quarter Revenue: Approximately $5.9 billion, reflecting an 8.3% increase on a reported basis.
- Fiscal Year Revenue: Approximately $21.8 billion, showing an 8.2% increase on a reported basis.
For the fourth quarter, organic revenue growth stood at 3.9%, while full-year organic growth was at 2.9%. These figures illustrate BD’s resilience in a challenging macroeconomic environment.
Future Outlook
Polen indicated that BD is taking proactive steps to unlock value, with expected growth across various segments. The company continues to monitor market challenges closely, particularly in pharmaceutical systems and academic research sectors.
Looking forward, BD anticipates delivering adjusted diluted earnings per share for fiscal 2025 at or above the midpoint of earlier guidance. This outlook reflects a commitment to maintaining strong operational performance.
Upcoming Conference Call
To discuss these results in detail, BD will host an audio webcast on November 6, 2025, at 8 a.m. ET. Interested parties can access the webcast via BD’s investor relations website.
This strategic CFO transition plan marks a new chapter for BD as it continues to navigate the complexities of the healthcare sector while striving to achieve its ambitious strategic goals.
